A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Clinical trial NCT02162888 · COMPLETED

Trial details

NCT number: NCT02162888
Sponsor: Eagle Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

Start date: 2013-11-01
Primary completion: 2014-11-01
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.